Scinai Immunotherapeutics (NASDAQ: SCNI) , a biopharma company focused on inflammation and immunology treatments and CDMO services, reported a $4.8 m ...

Scinai Immunotherapeutics Ltd.  ("Scinai", or the "Company"), a biopharmaceutical company focused on developing novel and innovative biological drug candidates for the treatment of inflammation and ...

Scinai Immunotherapeutics Ltd. , a biopharmaceutical company specializing in inflammation and immunology (I&I) biological ...

1. Title: Development of Anti-inflammatory Bispecific anti-TNF-α VHH anti-IL-6 Antibody Fusion for the Treatment of Inflammatory Retinal Diseases Elevated levels of pro-inflammatory cytokines ...

The webinar will explore PC111, a novel monoclonal antibody drug candidate with the potential to transform the treatment landscape for Pemphigus Vulgaris and Stevens-Johnson Syndrome/Toxic ...

Humanized, small size, strong affinity single domain antibodies (variable domain of heavy chain of heavy-chain antibody [VHH]) derived from camelids are promising alternatives.

Schematic overview of different antibody formats. Conventional mAb, HcAb and its derivative (i.e., nanobody, also referred to as the variable domain of the heavy chain of a HcAb or VHH).

They consist of one or more domains based on the small antigen-binding variable regions of heavy-chain-only antibodies (VHH). Nanobodies® have a number of potential advantages over traditional ...

Granite Bio is ready to rock 'n' roll, unveiling with $100 million and hopes of shaping new antibody treatments targeting several autoimmune diseases. The funding consists of a $30 million series ...

Full results from the trial evaluating Akeso’s first-in-class PD-1/VEGF bispecific antibody are expected to be presented later this year at a medical conference. 1 "The interim analysis results from ...

The FDA plans to reduce and potentially replace animal testing for developing monoclonal antibody therapies and other medications. AI-based computational models are expected to play a larger role ...